Barinthus Biotherapeutics

Barinthus Biotherapeutics plc
Company type	Public
Traded as	Nasdaq: BRNS
Industry	Vaccines; Immunotherapy; Biotechnology;
Founded	2016
Founder	Sarah Gilbert; Adrian V. S. Hill;
Headquarters	Oxford Science Park, Oxford, United Kingdom
Website	barinthusbio.com

Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.